Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Indaptus Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 5
- −14 vs. Q1 2025
- Shares held
- 307
- −686.7K (−100.0%) vs. Q1 2025
- Total value
- $3.23K
- −$374.5K (−99.1%) vs. Q1 2025
- New holders
- 1
- 0 more added
- Sold out
- 15
- 4 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting INDP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $1.15M |
| Q1 2026 | 6 | $128.5K |
| Q4 2025 | 4 | $93.7K |
| Q3 2025 | 5 | $57.9K |
| Q2 2025 | 5 | $3.23K |
| Q1 2025 | 19 | $377.8K |
| Q4 2024 | 20 | $539.6K |
| Q3 2024 | 18 | $750.2K |
| Q2 2024 | 21 | $1.26M |
| Q1 2024 | 17 | $1.31M |
| Q4 2023 | 19 | $1.06M |
| Q3 2023 | 16 | $1.57M |
| Q2 2023 | 15 | $1.11M |
| Q1 2023 | 15 | $1.08M |
| Q4 2022 | 18 | $838.5K |
| Q3 2022 | 18 | $1.22M |
| Q2 2022 | 17 | $1.31M |
| Q1 2022 | 17 | $6.81M |
| Q4 2021 | 15 | $10.5M |
| Q3 2021 | 15 | $4.24M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Indaptus Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SBI Securities Co., Ltd. | 156 | $1.64K | 0.00% | −4,244−96.5% | Reduced |
| Tower Research Capital LLC (TRC) | 108 | $1.14K | 0.00% | −3,385−96.9% | Reduced |
| Bank of America Corp | 31 | $327 | 0.00% | −67−68.4% | Reduced |
| FMR LLC | 10 | $105 | 0.00% | +10 | New |
| Wells Fargo & Company | 2 | $21 | 0.00% | −62−96.9% | Reduced |
| Vanguard Group Inc | 0 | $0 | 0.00% | −256,265−100.0% | Sold out |
| Investment House LLC | 0 | $0 | 0.00% | −128,851−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −124,967−100.0% | Sold out |
| Strategy Asset Managers LLC | 0 | $0 | 0.00% | −45,336−100.0% | Sold out |
| Pine Valley Investments Ltd Liability Co | 0 | $0 | 0.00% | −43,771−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −28,500−100.0% | Sold out |
| Vivaldi Capital Management, LLC | 0 | $0 | 0.00% | −24,000−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −13,073−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −12,872−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −884−100.0% | Sold out |
| Bangor Savings Bank | 0 | $0 | 0.00% | −350−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −87−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −17−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −7−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −1−100.0% | Sold out |